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In the recent manuscript “MelanomaDB:
a web tool for integrative analysis of
melanoma genomic information to
identify disease-associated molecular
pathways” (Trevarton et al., 2013) an inter-
esting dichotomy presents itself, which is
in fact more broadly applicable to the
field in general. In this work, the authors
introduce an integrative tool designed to
facilitate and organize disparate forms
of data relevant to melanoma, includ-
ing sequence, microarray, biological, drug
target, drug-ability, biomarker, pharmaco-
logical, clinical trial, survival, and pathway
information. It combines this data into
a single matrix, for the purpose of facil-
itating gene set analysis interpretation,
rational experimental design, interpreta-
tion of molecular profiles of tumors for
individual patients, and aiding in patient
stratification.
Included in their tool currently
or prospectively are data from the
DrugBank1, KEGGDrug2, theTherapeutic
Targets Database3, ClinicalTrials.gov4,
KEGG BRITE5, DrugEBIlity6, UniProt7,
the Secreted Protein Database8, KinBase9,
Gene Expression Omnibus (GEO)10,
Cancer Cell Line Encyclopedia11, the
Catalogue Of Somatic Mutations In
1DrugBank. http://www.drugbank.ca
2KEGGDrug. http://www.genome.jp/kegg/drug/
3Therapeutic Targets Database. http://bidd.nus.edu.
sg/group/cjttd/
4ClinicalTrials.gov. http://clinicaltrials.gov
5KEGGBRITE. http://www.genome.jp/kegg/brite.
html
6DrugEBIlity. (http://www.ebi.ac.uk/chembl/
drugebility/)
7UniProt. http://www.uniprot.org
8Secreted Protein Database. http://spd.cbi.pku.edu.
cn
9KinBase. http://kinase.com/kinbase/
10Gene Expression Omnibus. http://www.ncbi.nlm.
nih.gov/geo/
11Cancer Cell Line Encyclopedia. http://www.
broadinstitute.org/software/cprg/?q=node/11
Cancer (COSMIC)12, Matched Pair
Cancer Cell Lines13, Australia’s Melanoma
Genome Project14, The Cancer Genome
Atlas (TCGA) project15, Oncomine16, the
Broad Institute’s Melanoma Genomics
Portal17, as well as data from multiple
publications.
Certainly this may be seen as an asset.
No one group has the ability to generate
all the data needed for true systems biol-
ogy or pharmacology, and so, as a field we
are all dependent on data generated by oth-
ers. The MelanomaDB tool brings together
multiple forms of data that, while avail-
able from their individual sources, would be
challenging, time consuming, and require
specific knowledge of those multiple data
sources for the user to compile. Especially of
interest is the integration of the molecular
forms of gene data with those genes com-
monly mutated in metastatic melanomas,
and drug-ability information. Thus, the
authors aim to facilitate the fluent integra-
tion of disease-relevant information, a huge
problem in the field in general.
Unfortunately, there are also inherent
dangers for this type of approach. An obvi-
ous danger is that when compiling data
from multiple sources, one will be subject
to any flaws inherent in those data. That is,
one is heavily reliant on the work of other
groups that one has no detailed knowl-
edge of. Assessment of the reliability of the
12Catalogue Of Somatic Mutations In Cancer. http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/
13Matched Pair Cancer Cell Lines. http://www.sanger.
ac.uk/genetics/CGP/Studies/Matched/
14Australia’s Melanoma Genome Project.
http://www.melanoma.org.au/research/
melanoma-genome-project.html
15The Cancer Genome Atlas. http://cancergenome.
nih.gov
16Oncomine. http://www.oncomine.com/resource/
login.html
17Broad Institute’s Melanoma Genomics Portal. http://
www.broadinstitute.org/software/cprg/?q=node/46
component parts that are being assembled
from multiple data sources is difficult or
impossible. Nonetheless, all conclusions are
completely reliant on these data. Websites
that integrate data from other websites
clearly are susceptible to perpetuating data
problems or inaccuracies as well as poten-
tially amplifying their influence in the field.
Some forms of data will be more prob-
lematic than others. DNA sequence and
copy number should be relatively consis-
tent, due to DNAs stability, reproducibil-
ity, and ease of verification. The drug
databases will give an accurate picture of
the incomplete knowledge of the day, real-
izing that target and interacting pathway
information remains incomplete. mRNA
and microRNA expression is and will
remain subjective due to the technique and
reagents used during growth and/or har-
vest of either cell lines or patient samples.
Inclusion of gene set analysis approaches
clearly introduces an additional layer of
study-specific considerations.
For the DNA sequence data, the abil-
ity to repeat analysis provides a way to
catch potential errors, however, once erro-
neous data is entered into a database it will
likely remain there. The drug knowledge
databases are constantly being updated as
new information is obtained. mRNA (or
microRNA) expression may be the most
difficult to assess, as there is really no way
to exactly reproduce another group results,
and so there is no clear way to recognize or
filter out poorly done studies.
Certainly the MelanomaDB site is not
the first to be affected by these consider-
ations, as they are endemic to the field.
Careful consideration of one’s sources of
data, its reliability, and compatibility with
other forms of data seems requisite. While
recognizing that a detailed assessment of
multiple data sources is outside of the
scope for this (or any other) group, some
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consideration of what data to use and its
reliability are important if the field is to
make accurate and scientifically relevant
conclusions. Only by inclusion of high-
quality input data may one expect to draw
meaningful conclusions.
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